Clinical Care Options HIV - Managing Dyslipidemia in HIV-Infected Patients on Therapy: Switch Antiretrovirals or Add Lipid-Lowering Agents?

Module

Managing Dyslipidemia in HIV-Infected Patients on Therapy: Switch Antiretroviral Agents or Add Lipid-Lowering Agents?

Faculty:

Marshall J. Glesby, MD, PhD
James H. Stein, MD

CME CREDIT INFORMATION

Release Date: 09/09/08

Expiration Date: 09/08/09

Physicians: maximum of 1.75 AMA PRA Category 1 Credits™

Registered Nurses: 1.7 Nursing CE credits

Status: Please log in to view status

Marshall J. Glesby, MD, PhD, and James H. Stein, MD, review evidence, discuss cases, and answer questions on the strategy of switching antiretroviral therapy vs adding lipid-lowering drugs to manage HIV-infected patients with dyslipidemia.

Learning Objectives

Upon completion of this activity, participants should be able to:

Recall the effects that different antiretroviral classes, and specific drugs within classes, have on lipids
Discuss the results of recent trials attempting to improve lipid abnormalities in HIV-infected patients receiving antiretroviral agents
Describe the benefits associated with various lipid-lowering therapies in HIV-infected patients receiving antiretroviral agents
Summarize strategies to both prevent and control cardiovascular risk in HIV-infected patients on antiretroviral therapy

Downloadable Audio

Marshall J. Glesby, MD, PhD, and James H. Stein, MD, review evidence for managing HIV-infected patients with dyslipidemia—should one switch antiretroviral therapy or add lipid-lowering agents?

Download Audio

CCO Slideset

Managing Dyslipidemia in HIV-Infected Patients on Therapy

Marshall J. Glesby, MD, PhD, and James H. Stein, MD, review evidence for managing HIV-infected patients with dyslipidemia—should one switch antiretroviral therapy or add lipid-lowering agents?

Format: Microsoft PowerPoint (.ppt) | File size: 1.54 MB

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

CCO Treatment Updates

Managing Dyslipidemia in HIV-Infected Patients on Therapy: Switch Antiretrovirals or Add Lipid-Lowering Agents?